郑州微飒生物科技有限责任公司 咨询热线：0371-88821766
行业动态

行业动态

追踪行业前沿，洞察产业趋势

药效评价Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

期刊：Journal of medicinal chemistry发表年份：2009作者：Yaguo Zheng; Eyup Akgün; Kaleeckal G Harikumar; Jessika Hopson; Michael D Powers; Mary M Lunzer; Laurence J Miller; Philip S Portoghese
阅读更多 →

药效评价Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.

期刊：Chemical & pharmaceutical bulletin发表年份：2009作者：Tetsuji Noguchi; Naoki Tanaka; Toyoki Nishimata; Riki Goto; Miho Hayakawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Yoichi Niitsu; Fumitoshi Asai; Tomoko Ishizuka; Koichi Fujimoto
阅读更多 →

药效评价[Neuroreceptor mechanisms of the afobazole effect].

期刊：Eksperimental'naia i klinicheskaia farmakologiia发表年份：2009作者：S B Seredenin; M V Voronin
阅读更多 →

药效评价Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction.

期刊：European journal of pharmacology发表年份：2009作者：Arnaud Bocquet; Robert Létienne; Sylvie Sablayrolles; Luc De Vries; Michel Perez; Bruno Le Grand
阅读更多 →